On July 23, AKESO rose 4.15% in regular trading, trading at 104.3 HKD/share, with turnover of HKD 371 million. The stock was driven by multiple positive catalysts from its overseas partner Summit Therapeutics.

Summit recently disclosed the latest OS analysis from the global multi-center Phase III HARMONi study of ivonescimab: OS hazard ratios in both the ITT population and Western population improved to 0.76, highly consistent with the China HARMONi-A study results. The data has been submitted to the FDA to support BLA review. On the same day, Summit announced a collaboration with Arcus Biosciences to advance ivonescimab in combination with HIF-2alpha inhibitor casdatifan for clear cell renal cell carcinoma in an international multi-center clinical study, further expanding the indication landscape for ivonescimab.

These developments follow a series of recent catalysts for AKESO, including the first patient dosing in a Phase II study of its novel Trop2/Nectin-4 bispecific ADC combined with ivonescimab for advanced NSCLC, advancing the company's IO2.0 plus ADC2.0 dual-platform strategy.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)